Introduction {#s1}
============

Extracorporeal membrane oxygenation (ECMO) is an advanced form of mechanical life support for children with acute cardiorespiratory failure. While ECMO treatment supports systemic cardiorespiratory function, it is unclear whether it improves microcirculatory function and to what extent.

With the introduction of handheld vital microscopy, it has become possible to visualize the microcirculation in a non-invasive manner. This has offered insight into microcirculatory function, i.e., oxygen transport on a microcirculatory level. In several clinical settings, handheld vital microscopy has revealed the presence of microcirculatory disturbances despite normal systemic hemodynamics, thus possibly detecting otherwise unnoticed disturbed tissue oxygenation ([@B1]). These microcirculatory disturbances have been found to be independently associated with increased mortality risk ([@B2]--[@B4]).

The microcirculation of the sublingual mucosa has shown to be a good representation of other microvascular beds under a variety of pathophysiologic conditions ([@B5]--[@B7]). The sublingual microcirculation has shown to be predictive for survival in adult patients treated with venoarterial (VA) ECMO for cardiogenic shock and has even been proposed as a novel marker for successful weaning from VA ECMO after cardiogenic shock in adults ([@B8], [@B9]). Top et al. investigated the buccal microcirculation in neonates with severe respiratory failure treated with VA ECMO and showed that the buccal microcirculation was preserved after start of ECMO treatment ([@B10]). However, it remains unclear how the buccal microcirculation relates to other microvascular beds including the sublingual microcirculation. Whether ECMO treatment affects the sublingual microcirculation has not yet been investigated in the neonatal and pediatric population.

The aim of our study is to assess the effect of ECMO treatment on the sublingual microcirculation in a neonatal and pediatric population. We hypothesize that (1) the sublingual microcirculation improves after start of ECMO treatment, (2) that microcirculatory parameters differ between venovenous (VV) and VA ECMO, and (3) that insufficient recovery of microcirculatory disturbances during ECMO treatment predicts mortality.

Methods {#s2}
=======

Study Design, Population, and Setting
-------------------------------------

We performed a prospective longitudinal observational study at the ICU of a tertiary university children\'s hospital, which serves as the national ECMO center, between April 2016 and September 2018. Consecutive ECMO patients were included to acquire a representative sample of the ECMO population of our institute. The study was approved by the local medical ethical review board (Medical Research Ethics Committee Erasmus Medical Center Rotterdam). Informed consent was waived as standard therapy was monitored through non-invasive techniques in accordance with hospital guidelines. Patients aged \<18 years treated with ECMO irrespective of ECMO modus (VV or VA ECMO) and primary diagnosis were included in the study. Patients needed to be fully cooperative or sufficiently sedated in order to perform microcirculatory measurements. If a patient did not meet this criterion either before or immediately after start of ECMO treatment, he or she was excluded. The primary study parameters were the microcirculatory parameters, as described below.

Data Collection
---------------

The sublingual microcirculation was assessed with the Cytocam (Braedius Medical, Huizen, the Netherlands). The Cytocam is a handheld vital microscopy incorporated with incident dark field illumination, high magnification lenses and a computer-controlled high-resolution image sensor ([@B11]). International expert consensus guidelines were followed for both image acquisition and analysis ([@B12], [@B13]). The handheld probe was gently positioned on the sublingual mucosa and five clips, each with a duration of 6 s, were recorded at the following time points: before start of ECMO treatment, within 24 h after start ECMO treatment, daily during ECMO treatment, and finally after ECMO treatment was terminated up to 2 h after decannulation. Image quality was assessed using the quality score developed by Massey et al. ([@B14]). If quality criteria were not met, images were excluded from analysis. Image analysis was performed offline using semi-automated software AVA 3.2 (MicroVision Medical, Amsterdam, the Netherlands) by an experienced researcher (ÖE), who was blinded to the origin of the clips. Image analysis yielded the following functional parameters for all microcirculatory vessels (diameter \<100 μm) and for all small vessels, mainly capillaries, (diameter \<20 μm): total vessel density (TVD~all~/TVD~\<20μ*m*~, mm/mm^2^), proportion perfused vessels (PPV~all~/PPV~\<20μ*m*~, %), perfused vessel density (PVD~all~/PVD~\<20μ*m*~, mm/mm^2^), microcirculatory flow index (MFI~all~/MFI~\<20μ*m*~, score between 0 and 3) and heterogeneity index of flow (HI, score between 0 and 1) ([@B12]). TVD quantifies the total vessel area visible in the frame, while PPV gives the number of perfused vessels per total number of visible vessels in the frame. PVD describes the functional vessel area visible in the frame, calculated through the multiplication of TVD and PPV. MFI is a semi-qualitative score to describe the quality of flow. To obtain MFI, the screen is divided into four quadrants and each quadrant is assigned a score between 0 and 3, where 0 = no flow, 1 = intermittent flow, 2 = sluggish flow and 3 = continuous flow. The average of the scores of the four quadrants is the MFI. To account for variability between measured areas, HI can be calculated through the equation \[*(highest value---lowest value)/mean value*\].

Baseline and ECMO characteristics, routine clinical and hemodynamic parameters and laboratory values were collected from electronic records and the PEdiatric Logistic Organ Dysfunction 2 (PELOD-2) score, the inotrope score (IS), and the vasoactive-inotrope score (VIS) were calculated ([@B15], [@B16]). Also, mortality on ECMO, ICU length of stay, and survival were assessed at the end of the study period.

ECMO Treatment
--------------

Initiating ECMO support, modus and ECMO settings were according to a well-established hospital-based ECMO protocol that did not change over time. Depending on the age of patients, cannulation in neonates was always by surgical neck dissection and adapted Seldinger technique. For pediatric patients, femoral surgical approaches with or without a neck cannula were used. The ECMO circuit comprised the Medos DP3 centrifugal pump and either the Medos HILITE LT or the iLA Activve Membrane Ventilator oxygenators. During ECMO treatment patients received continuous unfractionated heparin as anticoagulation with dose adjustments following hospital treatment guidelines.

Statistical Analysis
--------------------

Continuous data are presented as median (1st quartile−3rd quartile) and categorical data as frequency (percentage). To compare continuous variables between survivors and non-survivors, between VV and VA ECMO, and between types of primary diagnoses, the Mann-Whitney *U*-test and the Kruskal-Wallis test were used. To account for the fact that microcirculatory measurements could not always be performed on a daily basis, measurements were divided over the following time points for analysis: before start of ECMO, after start ECMO/ECMO day 1, ECMO day 2/3, ECMO day 4/5, ECMO day 6/7 and after stop ECMO treatment. If the patient was indeed measured on a daily basis from day 2 onwards, the first measurement in the 48 h was used for analysis.

For univariable analyses of repeated measures, linear mixed models were built for microcirculatory parameters and global hemodynamic parameters with time point as the single independent variable, to assess whether these parameters differed between time points. In addition, linear mixed models were built for microcirculatory parameters with time point and another independent variable to explore which baseline and ECMO demographics and global hemodynamic parameters (parameters mentioned in [Tables 1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}) affected microcirculatory parameters.

###### 

General demographics study population.

                                    **Total**           **Survivors**       **Non-survivors**   ***p*-value**
  --------------------------------- ------------------- ------------------- ------------------- ---------------
  Patients                          34                  19 (56%)            15 (44%)            
  Female                            16 (47%)            8 (42%)             8 (53%)             0.515
  Age (years)                       0.27 (0.01--2.23)   0.02 (0.00--1.47)   0.50 (0.04--2.67)   0.089
  Neonate                           16 (47%)            12 (63%)            4 (27%)             0.034\*
  Weight (kg)                       5.0 (3.3--13.3)     3.5 (3.3--9.4)      9.0 (3.5--14.0)     0.190
  PELOD-2 score on day start ECMO   12 (9--17)          10 (8--13)          13 (11--17)         0.228

*Continuous data are presented as median (Q1-Q3), categorical data as n (%). PELOD-2 score, PEdiatric Logistic Organ Dysfunction 2 score. \*p-value \<0.05 is considered statistically significant*.

###### 

ECMO specific demographics study population.

                                      **Total (*n* = 34)**   **Survivors (*n* = 19)**   **Non-survivors (*n* = 15)**   ***p*-value**
  ----------------------------------- ---------------------- -------------------------- ------------------------------ ---------------
  **Type ECMO:**                                                                                                       0.350
  VV                                  12 (35%)               8 (42%)                    4 (27%)                        
  VA                                  22 (65%)               11 (58%)                   11 (73%)                       
  **Type primary diagnosis:**                                                                                          0.374
  Respiratory                         15 (44,1%)             10 (53%)                   5 (33%)                        
  Cardiac                             13 (38,2%)             7 (37%)                    6 (40%)                        
  ECPR                                6 (17,6%)              2 (10%)                    4 (27%)                        
  **Primary indication for ECMO:**                                                                                     
  Respiratory insufficiency           3 (8.8%)               2                          1                              
  PPHN/PHT                            5 (14.7%)              3                          2                              
  MAS/PHT                             3 (8.8%)               3                          0                              
  CDH/PHT                             3 (8.8%)               2                          1                              
  Near drowning                       3 (8.8%)               1                          2                              
  Septic shock                        1 (2.9%)               0                          1                              
  Cardiac failure                     4 (11.8%)              3                          1                              
  Cardiomyopathy                      4 (11.8%)              1                          3                              
  Myocarditis                         1 (2.9%)               1                          0                              
  Cardiogenic shock                   1 (2.9%)               1                          0                              
  ECPR                                6 (17.6%)              2                          4                              
  **Duration ECMO treatment (hrs)**   142.6 (82.4--308.5)    116.5 (81.5--231.5)        242.0 (89.0--366.5)            0.215

*Continuous data are presented as median (Q1-Q3), categorical data as n (%). CDH, congenital diaphragmatic hernia; ECMO, extracorporeal membrane oxygenation; ECPR, extracorporeal cardiopulmonary resuscitation; MAS, meconium aspiration syndrome; PHT, pulmonary hypertension; PPHN, persisting pulmonary hypertension in the newborn; VA, venoarterial; VV, venovenous. p-value \<0.05 is considered significant*.

###### 

Observed data per time point.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Parameter**              **Before start ECMO (*n* = 13)**   **After start ECMO/on day 1**\   **ECMO day 2 or 3**\   **ECMO day 4 or 5**\    **ECMO day 6 or 7**\    **After stop ECMO**\    ***p*-value**
                                                                **(*n* = 29)**                   **(*n* = 24)**         **(*n* = 9)**           **(*n* = 7)**           **(*n* = 11)**          
  -------------------------- ---------------------------------- -------------------------------- ---------------------- ----------------------- ----------------------- ----------------------- ---------------
  TVD~all~ (mm/mm^2^)        24.59 (20.71--26.41)               25.48 (23.15 - 28.35)            24.47 (23.13- 26.75)   28.15 (26.80 - 30.09)   27.95 (23.36 - 31.80)   25.35 (23.61 - 26.75)   0.374

  PPV~all~ (%)               98.78 (96.49 - 99.16)              99.12 (97.43--99.78)             98.82 (97.27--100)     99.27 (98.01--99.75)    99.74 (98.88--99.90)    99.23 (97.76--100)      0.569

  PVD~all~ (mm/mm^2^)        24.03 (20.14--26.14)               25.38 (23.10--27.99)             24.38 (22.92--25.82)   28.07 (25.90--29.92)    27.43 (23.31--31.71)    25.26 (23.11--26.30)    0.371

  MFI~all~                   2.78 (2.48--2.87)                  2.87 (2.76- 3)                   2.83 (2.73--3)         2.85 (2.64--3)          2.92 (2.64--3)          2.89 (2.73--2.98)       0.880

  HI~MFI~                    0.09 (0.09--0.17)                  0.07 (0--0.13)                   0.09 (0--0.11)         0.13 (0--0.13)          0.04 (0--0.10)          0.05 (0.02--0.15)       0.728

  TVD~\<20μ*m*~ (mm/mm^2^)   21.70 (18.80--23.59)               22.75 (20.68--24.68)             21.47 (20.41--23.90)   26.41 (24.30--26.90)    25.83 (20.63--28.99)    21.91 (20.51--24.23)    0.378

  PPV~\<20μ*m*~ (%)          98.62 (96.17--99.40)               99.08 (97.35--99.74)             98.70 (96.93--100)     99.14 (97.87--99.70)    99.71 (98.73--99.89)    99.13 (97.35--100)      0.579

  PVD~\<20μ*m*~ (mm/mm^2^)   21.22 (18.45--23.35)               22.18 (20.40--24.35)             21.16 (19.67--23.40)   24.48 (24.23--26.73)    25.31 (20.58--28.91)    21.65 (19.52--24.04)    0.388

  MFI~\<20μ*m*~              2.38 (2.06--2.71)                  2.75 (2.50--3)                   2.67 (2.50--3)         2.67 (2.33--3)          2.75 (2.33--3)          2.75 (2.44--3)          0.381

  MAP (mmHg)                 55 (42--70)                        57 (48--66)                      58 (51--71)            48 (46--59)             55 (43--58)             47 (38--52)             0.053

  HR (bpm)                   157 (136--166)                     147 (121--156)                   134 (106--150)         119 (114--123)          131 (127--147)          145 (122--154)          0.003\*

  CVP (mmHg)                 9 (6--10)                          11 (5--17)                       10 (6--18)             (--)                    (--)                    (--)                    0.587

  Fluid balance (ml/kg/d)    42 (8--75)                         40 (26--69)                      −11 (-40--65)          12 (−26--116)           −18 (−21--61)           9 (−4--44)              0.193

  pH                         7.26 (7.18--7.34)                  7.34 (7.23--7.38)                7.36 (7.33--7.42)      7.33 (7.32--7.42)       7.41 (7.29--7.47)       7.29 (7.22--7.44)       0.205

  PaO~2~ (kPa)               11.3 (7.0--18.5)                   10.8 (8.0--17.2)                 8.7 (6.8--11.3)        10.3 (8.9--11.6)        11.1 (6.9--18.3)        16.7 (11.3--20.9)       0.167

  PaCO~2~ (kPa)              6.4 (5.2--9.1)                     5.7 (5.0--6.3)                   5.8 (5.5--6.1)         5.6 (5.3--6.6)          5.5 (5.3--7.1)          6.1 (5.2--8.0)          0.017\*

  SaO~2~ (%)                 90 (83--99)                        96 (93--100)                     95 (89--98)            97 (93--98)             98 (96--100)            99 (98--100)            0.008\*

  Hemoglobin (mmol/L)        7.6 (5.9--8.8)                     6.7 (6.0--7.7)                   7.5 (6.9--7.9)         6.7 (6.5--7.3)          6.5 (6.3--6.9)          6.5 (6.4--6.8)          0.085

  Hematocrit (L/L)           0.35 (0.25--0.39)                  0.33 (0.29--0.36)                0.34 (0.32--0.36)      0.32 (0.30--0.32)       0.33 (0.30--0.34)       0.32 (0.29--0.35)       0.838

  Lactate (mmol/L)           4.1 (1.4--6.0)                     3.6 (1.9--8.5)                   1.4 (1.2--3.2)         1.3 (1.0--4.9)          1.5 (0.8--3.5)          0.8 (0.6--1.3)          \<0.001\*

  IS                         12 (0--48)                         10 (0--38)                       10 (0--24)             0 (0--5)                0 (0--0)                0 (0--4)                0.017\*

  VIS                        72 (0--98)                         27 (5- 80)                       10 (0--36)             0 (0--5)                2 (0--49)               5 (2--14)               0.002\*

  On ECMO                    0 (0%)                             34 (100%)                        31 (91%)               22 (64%)                17 (50%)                0 (0%)                  NA

  Mortality                  0 (0%)                             0 (0%)                           2 (6%)                 4 (12%)                 5 (15%)                 12 (35%)                NA
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Table shows the observed raw data per time point. The last column shows the p-values based on the univariable linear mixed models. Continuous data are presented as median (Q1-Q3), categorical data as n (%). CVP, central venous pressure; ECMO, extracorporeal membrane oxygenation; HI, heterogeneity index of flow; HR, heart rate; IS, inotrope score; MAP, mean arterial pressure; MFI, microcirculatory flow index; NA, not applicable; PaCO~2~, partial arterial carbon dioxide pressure; PaO~2~, partial arterial oxygen pressure; PPV, proportion perfused vessels; PVD, perfused vessel density; SaO~2~, arterial oxygen saturation; TVD, total vessel density; VIS, vasoactive inotrope score; \* significant change over time points (univariable linear mixed models, p \<0.05)*.

For multivariable analyses of repeated measures, linear mixed models (continuous outcome parameter: PVD) and logistic regression models based on generalized estimating equations with a binomial error distribution and logit link function (categorical outcome parameter: MFI \>2.6) were built. MFI ≤2.6 has been proposed and shown, but not yet validated in children, as the threshold to identify a disturbed microcirculation ([@B3], [@B4]). Significant independent variables from the univariable analyses were tested in these multivariable analyses. The independent variables tested for PVD~all~ and PVD~\<20μ*m*~: pediatric patient, sex, sildenafil treatment, plasma transfusion in the last 24 h, crystalloids transfusion in the last 24 h, partial O~2~ pressure (PaO~2~, kPa), and norepinephrine (μg/kg/min); for MFI~all~:, pediatric patient: sex, PaO~2~ (kPa), norepinephrine (μg/kg/min), duration ECMO treatment (hours), mean arterial pressure (MAP, mmHg), hemoglobin (L/L), and fraction inspired O~2~ (FiO~2~, %) of the sweep gas flow; for MFI~\<20μ*m*~: pediatric patient, norepinephrine (μg/kg/min), FiO~2~ (%), MAP (mmHg), hemoglobin (L/L), and FiO~2~ of the sweep gas flow (%). The stepwise backward method with a *p*-value selection threshold of 0.2 was then applied to obtain the final multivariable model. Time point was forced into both univariable and multivariable models, irrespective of the *p*-value. A random intercept was included in the linear mixed models to account for the within-subject correlations. The linear mixed models account for missing data in the outcome and no form of data imputation was used.

Receiver-operating-characteristic (ROC) curves were built to assess the predictive value of microcirculatory parameters per time point for mortality on ECMO and overall mortality. Two-sided *p*-values lower than 0.05 were considered statistically significant, but a Bonferroni-adjusted significance level of 0.008 was used for the ROC analyses. Statistical analysis was performed in IBM SPSS statistics 24 (IBM, Armonk, NY, USA).

Results {#s3}
=======

Demographics
------------

[Figure 1](#F1){ref-type="fig"} shows the flow chart for inclusion. Thirty-seven consecutive patients were included in the study. Three patients were excluded from analysis as the collected images did not meet quality criteria. [Table 1](#T1){ref-type="table"} describes the general demographics of the study population. The study population comprised 34 patients, with a median age of 0.27 years, 16 neonates (47%), 16 females (47%), and a median PELOD-2 score of 12 (mortality risk of \>30%). [Table 2](#T2){ref-type="table"} describes ECMO-specific demographics. Twelve patients (35%) received VV ECMO treatment and 22 patients (65%) VA ECMO treatment. Primary indications for ECMO treatment included 15 respiratory diagnoses (44%), 13 cardiac diagnoses (38%), and 6 extracorporeal cardiopulmonary resuscitation (ECPR) cases (18%). Four of the 13 cardiac diagnoses (12%) were cyanotic heart diseases. The median duration of ECMO treatment was 142.6 h. Type of ECMO, primary indications for ECMO treatment, and duration of ECMO treatment did not significantly differ between survivors and non-survivors.

![Flowchart inclusion study population.](fped-07-00272-g0001){#F1}

Univariable Analyses of Microcirculatory and Global Hemodynamic Parameters
--------------------------------------------------------------------------

[Table 3](#T3){ref-type="table"} shows the microcirculatory and global hemodynamic parameters per time point. Microcirculatory measurements were possible in 38% of the study population before start of ECMO treatment, in 85% after start of ECMO treatment, in 77% on day 2 or 3, in 41% on day 4 or 5 and on day 6 or 7 and in 50% after successful weaning from ECMO. Microcirculatory parameters did not change after start of and during ECMO treatment, while global hemodynamic parameters did show improvement over time. Heart rate, partial CO~2~ pressure (PaCO~2~), serum lactate, IS and VIS decreased over time, while arterial O~2~ saturation increased. Microcirculatory parameters did not significantly differ between VV and VA ECMO or between types of primary diagnosis. In addition, microcirculatory parameters were not different for patients with cyanotic heart disease. The 62% of ECMO patients who could not be measured before the start of ECMO treatment did not have different microcirculatory parameters at the consecutive time points than the 38% of ECMO patients who were measured before ECMO was initiated (*p* \> 0.05). No differences could be found between the two groups in PELOD-2 score, type of ECMO, primary indication for ECMO, and mortality rates (*p* \> 0.05).

Multivariable Analyses of Microcirculatory Parameters PVD and MFI
-----------------------------------------------------------------

[Table 4](#T4){ref-type="table"} summarizes the results of the linear mixed models for PVD. Both PVD~all~ and PVD~\<20μ*m*~ were lower if the patient was a pediatric patient (\> 28 days old) or female or had received plasma transfusion in the last 24 h before measurement. Both PVD~all~ and PVD~\<20μ*m*~ were lower if continuous intravenous infusion of norepinephrine was administered at a higher dose or if PaO~2~ increased. PVD was higher if the patient received sildenafil or crystalloids in the last 24 h before measurement. [Table 5](#T5){ref-type="table"} summarizes the results of the logistic regression models for MFI \> 2.6. The probability of MFI~all~ \> 2.6 was lower in pediatric patients than in neonates. The probability of MFI~all~ \> 2.6 was higher when patients were on ECMO for a longer period, MAP was higher, or FiO~2~ of the sweep gas flow was set higher. The probability of MFI~all~ \> 2.6 was lower when PaO~2~ was higher. The probability of MFI~\<20μ*m*~ \> 2.6 was higher with higher MAP or FiO~2~ but decreased with higher hemoglobin levels.

###### 

Multivariable linear mixed models for PVD~all~ and PVD~\<20μ*m*~.

  **Repeated measures mixed model: PVD~**all**~**        **Estimate B**   **95% CI**       ***p*-value**
  ------------------------------------------------------ ---------------- ---------------- -------------------
  Intercept                                              28.321           24.214--32.429   \<0.001
  Time point                                                                               0.188
    Before start ECMO                                    1.737            −1.242--4.715    0.247
    After start ECMO/on day 1                            2.856            0.441--5.270     0.021
    ECMO day 2 or 3                                      1.012            −1.550--3.574    0.431
    ECMO day 4 or 5                                      1.455            −1.529--4.439    0.332
    ECMO day 6 or 7                                      2.232            −1.025--5.488    0.174
    After stop ECMO                                      0 (reference)    --               --
  Pediatric patient (\>28 days old) (c)                  −2.294           −4.381--0.207    0.032
  Male (c)                                               1.490            −0.486--3.466    0.134
  PaO~2~ (kPa)                                           −0.118           −0.223--0.012    0.029
  No sildenafil treatment (c)                            −2.165           −4.724--0.394    0.095
  No plasma transfusion in last 24 h (c)                 1.339            −0.412--3.091    0.131
  No crystalloids administration in last 24 h (c)        −2.400           −4.342--0.458    0.016
  Dose continuous IV norepinephrine (μg/kg/min)          −3.996           −7.417--0.580    0.023
  **Repeated measures mixed model: PVD**~**\<20μ*m***~   **Estimate B**   **95% CI**       ***p*****-value**
  Intercept                                              26.017           22.097--29.936   \<0.001
  Time point                                                                               0.077
    Before start ECMO                                    2.657            −0.210--5.524    0.069
    After start ECMO/on day 1                            3.627            1.300--5.955     0.003
    ECMO day 2 or 3                                      2.043            −0.427--4.513    0.103
    ECMO day 4 or 5                                      1.840            −1.034--4.714    0.205
    ECMO day 6 or 7                                      2.518            −0.623--5.659    0.113
    After stop ECMO                                      0 (reference)    --               --
  Pediatric patient (\>28 days old) (c)                  −3.192           −5.159--1.225    0.002
  Male (c)                                               1.260            −0.597--3.116    0.176
  PaO~2~ (kPA)                                           −0.132           −0.233--0.030    0.012
  No sildenafil treatment (c)                            −2.783           −5.201--0.365    0.025
  No plasma transfusion in last 24 hours (c)             1.716            0.032--3.399     0.046
  No crystalloids administration in last 24 hours (c)    −2.727           −4.590--0.865    0.005
  Dose continuous IV norepinephrine (μg/kg/min)          −3.667           −6.931--0.404    0.028

*C, categorical variable; CI, confidence interval; ECMO, extracorporeal membrane oxygenation; PaO~2~, partial O~2~ pressure; PVD, perfused vessel density*.

###### 

Repeated measures logistic regression (GEE) models for MFI~all~ \> 2.6 and MFI~\<20μ*m*~ \> 2.6.

  **Repeated measures logistic regression models: MFI~**all**~ \> 2.6**                **Odds ratio**   **95% CI**       ***p*-value**
  ------------------------------------------------------------------------------------ ---------------- ---------------- -------------------
  Intercept (baseline odds)                                                            0.652            0.018--23.460    0.815
  Time point                                                                                                             0.336
    Before start ECMO                                                                  0.188            0.017--2.127     0.188
    After start ECMO/on day 1                                                          0.045            0.003--0.663     0.045
    ECMO day 2/3                                                                       0.036            0.002--0.667     0.036
    ECMO day 4/5                                                                       0.021            0.000--1.327     0.021
    ECMO day 6/7                                                                       0.064            0.003--1.199     0.064
    After stop ECMO                                                                    1 (reference)    --               --
  Pediatric patient (\>28 days old) (c)                                                0.311            0.063--1.536     0.152
  Duration ECMO (hrs)                                                                  1.009            1.002--1.015     0.009
  MAP (mmHg)                                                                           1.068            0.989--1.153     0.093
  PaO~2~ (kPa)                                                                         0.892            0.836--0.953     0.001
  FiO~2~ of sweep gas flow ECMO (%)                                                    1.026            0.997--1.057     0.077
  **Repeated measures logistic regression models: MFI**~**\<20μ*m***~ **\>** **2.6**   **Odds ratio**   **95% CI**       ***p*****-value**
  Intercept (baseline odds)                                                            1.843            0.025--135.438   0.780
  Time point                                                                                                             0.149
    Before start ECMO                                                                  0.047            0.004--0.583     0.017
    After start ECMO/on day 1                                                          0.449            0.097--2.070     0.304
    ECMO day 2/3                                                                       0.204            0.026--1.612     0.132
    ECMO day 4/5                                                                       0.354            0.033--3.831     0.392
    ECMO day 6/7                                                                       0.692            0.065--7.424     0.761
    After stop ECMO                                                                    1 (reference)    --               --
  FiO~2~ (%)                                                                           1.022            0.996--1.048     0.101
  Hemoglobin (mmol/L)                                                                  0.612            0.354--1.057     0.078
  MAP (mmHg)                                                                           1.050            1.008--1.094     0.019

*C, categorical variable; CI, confidence interval; FiO~2~, fraction inspired oxygen; MAP, mean arterial pressure; MFI, microcirculatory flow index; PaO~2~, partial oxygen pressure*.

Outcome
-------

Twelve patients (35%) died during ECMO treatment, as ECMO treatment was stopped due to futility, and 3 patients (9%) died after ECMO treatment before ICU discharge. Leading causes of death during ECMO treatment were multi-organ failure (*n* = 5), severe brain damage and multi-organ failure (*n* = 4), severe brain damage (*n* = 2), and no treatment options (*n* = 1). Leading causes of death after ECMO treatment were no therapeutic options (*n* = 1), severe brain damage (*n* = 1) and untreatable pulmonary hypertension (*n* = 1). The median ICU length of stay was 15 days ([@B11]--[@B23]). Before start of ECMO treatment, there were no significant differences between survivors and non-survivors in global systemic hemodynamics or need for vasoactive drugs. Microcirculatory parameters did not differ between survivors and non-survivors on all time points separately. None of the microcirculatory parameters measured before start of ECMO treatment, after start of ECMO treatment or on day 2 or 3 of ECMO treatment could predict mortality on ECMO or overall mortality as none of the parameters had a significant area under the curve in the ROC curve analysis, summarized in [Table S1](#SM1){ref-type="supplementary-material"}.

Discussion {#s4}
==========

In our study with consecutively included patients, an effect of ECMO treatment on the sublingual microcirculation could not be demonstrated. Microcirculatory parameters did not change immediately after starting ECMO, nor during or after ECMO treatment. Microcirculatory parameters did not significantly differ between VV and VA ECMO. Multivariable analyses showed that PVD values were influenced by patients\' age, sex, plasma transfusion, infusion of norepinephrine, PaO~2~ levels, sildenafil treatment, and resuscitation with crystalloids. The probability of having an MFI \> 2.6 was influenced by patients\' age, MAP, FiO~2~ settings, PaO~2~ levels, and hemoglobin levels. Additionally, microcirculatory parameters did not significantly differ between survivors and non-survivors and did not predict mortality on ECMO or overall mortality.

In contrast to our hypothesis, the microcirculation did not change after the initiation of ECMO treatment in our study population, despite the effects of ECMO on systemic hemodynamics. ECMO treatment was started in patients with cardiovascular and/or respiratory failure when conventional treatment fell short in the support of global systemic hemodynamics. After ECMO initiation global systemic hemodynamics improved and the need for vasoactive and inotropic drugs and fluid resuscitation decreased. However, microcirculatory parameters appeared largely unaffected both before and immediately after initiation of ECMO treatment. As shown, PPV and MFI values were high before initiation of ECMO treatment and remained high at consecutive time points. Statistical analysis did not reveal specified patient groups in which the microcirculation was compromised before the initiation of ECMO treatment or changed after initiation of ECMO treatment. In contrast to adult studies in which the microcirculation improved in patients with cardiogenic shock treated with VA ECMO, type of ECMO and type of primary diagnosis (circulatory vs. respiratory) did not define groups in which ECMO treatment improved the microcirculation ([@B8], [@B9]). Similarly, nor PELOD-2 score, IS or VIS defined a specific group with an affected microcirculation that improved during ECMO treatment. There are several possible explanations for why the microcirculation was unaffected by ECMO treatment in our study. Due to clinical instability and technical and logistic issues, the microcirculation could only be assessed in 38% of patients before the initiation of ECMO. This possible selection bias could have affected the results. However, the patients who were not measured before ECMO treatment did not differ from the patients who were measured based on PELOD-2 score, type of ECMO, the primary indication for ECMO, and overall mortality. Additionally, the microcirculation did not differ at consecutive time points between these two groups. This suggests that the possible selection bias does not explain the lack of microcirculatory compromise and subsequent absence of change in the microcirculatory parameters over time in our study. Another explanation would be that ECMO treatment may have been initiated before global systemic hemodynamics deteriorated and influenced microcirculatory parameters. Also, despite critical illness and altered global systemic hemodynamics, which both affect microcirculatory function, the microcirculation has auto-regulatory mechanisms to preserve blood flow and tissue oxygenation ([@B17]). These explanations are supported by the relatively low lactate levels at the start of ECMO treatment. Finally, our study population may have been too small or heterogeneous to show effects or observe differences over time. However, this is not the first study to find an unaltered microcirculation during ECMO treatment. Similar to our results, in neonates with severe respiratory failure treated with VA ECMO, Top et al. reported that the PVD of the buccal microcirculation was unaltered after ECMO treatment was started ([@B10]). In contrast to our findings, Top et al. also found that after successful weaning from ECMO PVD was higher than after starting ECMO treatment ([@B18]).

In contrast to our expectations, microcirculatory parameters did not significantly differ between VV and VA ECMO. VV ECMO is generally started for respiratory insufficiency. As VA ECMO is started for cardiac failure or cardiorespiratory failure, more effects on the microcirculation were expected both before and after the initiation of VA ECMO. After starting VV ECMO treatment, hypoxia was resolved quickly. Similarly, hemodynamic instability was more often than not resolved quickly after starting VA ECMO, apparent by declining need of inotropic and vasoactive drugs. Then, for both types of ECMO, global systemic hemodynamics are restored before the microcirculation could deteriorate or the microcirculation is preserved despite altered global systemic hemodynamics. Another explanation could be that patients with pulmonary hypertension \[*n* = 5 (42% of VV ECMO patients)\] treated with VV ECMO are more comparable to VA ECMO patients than one would expect. Patients with pulmonary hypertension can present with hemodynamic instability, not different from patients with cardiac failure. However, these patients with pulmonary hypertension are treated with VV ECMO as this is often times sufficient to resolve the pulmonary hypertension and indirectly the hemodynamic instability that goes along with it ([@B19], [@B20]). These VV ECMO patients and VA ECMO patients before treatment might then have similar hemodynamics and similar microcirculatory properties while being treated with different ECMO entities.

PVD is used to assess the functional vessel density of the microcirculation, a surrogate for the diffusive capacity, i.e., the distance O~2~ covers from the RBC to the tissue cell ([@B12]). Multivariable analyses showed that age group, sildenafil treatment, and resuscitation with crystalloids had the biggest impact on PVD. PVD was lower in pediatric patients than in neonatal patients and in females than in males. This aligns with findings from several observational studies performed in healthy neonates and children, wherein these studies vessel density of cutaneous and buccal microcirculation declined over the first few weeks of life and vessel density of cutaneous microcirculation was lower in females than in males ([@B21]--[@B24]). Our comparable findings support the accuracy of the technique used, because, despite these being highly complex and critically ill children, the handheld vital microscopy yielded results in which the effect of age and sex on the microcirculation could still be distinguished from the other multiple factors affecting the microcirculation. A possible explanation for age-related differences is the developmental changes of the cardiovascular system, which have not yet been thoroughly investigated for the microcirculation ([@B25]). PVD was also higher in (neonatal) patients treated with sildenafil for pulmonary hypertension. As sildenafil decreases vascular resistance through vasodilation, blood flow through capillaries increases, which may account for the increase of PVD. Similar effects were assessed with handheld vital microscopy in an animal study on sildenafil treatment and cardiorespiratory resuscitation by Wu et al. ([@B26]). Although our data also suggest that norepinephrine decreases PVD, this effect was only clinically relevant if high doses (\>1.0 μg/kg/min) were administered. This might explain why Buijs et al. found that catecholaminergic drugs, including norepinephrine, improved global systemic hemodynamics but did not alter the microcirculation in neonates, as patients in their study only received a median dose of 0.11 μg/kg/min (IQR: 0.3) ([@B27]).

MFI is a qualitative measure of microvascular blood flow velocity and describes the convective component of the microcirculation ([@B12]). An MFI ≤2.6 is considered to be disturbed flow, though this has not yet been validated in children ([@B3], [@B4]). In our study, MAP and PaO~2~ levels had the biggest influence on MFI~all~, while hemoglobin levels had the biggest impact on MFI~\<20μ*m*~. MAP was also found to influence the quality of flow and, thus, there seemed to be no loss of hemodynamic coherence throughout ECMO treatment. As systemic hemodynamics improved as MAP increased, this increased the probability of having an MFI \>2.6. Interestingly, our study also found to have decreased probabilities for having an MFI \>2.6 with higher PaO~2~ levels, while having higher probabilities with higher FiO~2~. One would expect a patient with the need for higher FiO~2~ to have lower saturations and lower PaO~2~ values, given that other hemodynamic parameters are unaltered. However, it is not understood why a patient who requires higher FiO~2~ and has lower PaO~2~ would be more likely to have a better blood flow quality compared to a patient who requires less FiO~2~ and has higher PaO~2~ levels. Finally, increasing levels of hemoglobin increased the probability of having an MFI \>2.6. A similar finding was reported in an animal study, in which after blood transfusions hemoglobin increased concomitantly with increasing renal blood flow velocity ([@B28]). In contrast, RBC transfusions in anemic preterm infants and children improved both hemoglobin levels and PVD but did not affect MFI values ([@B29], [@B30]).

While previous studies performed in adults demonstrated the predictive value of microcirculatory parameters for outcome, our study was not able to reach the same conclusion. The sublingual microcirculation did not significantly differ between survivors and non-survivors. Subsequently, sublingual microcirculatory parameters before starting ECMO treatment, after starting ECMO treatment, or on day 2 or 3 could not predict mortality on ECMO or overall mortality. Although we expected that the microcirculation in non-survivors would be compromised before initiation of ECMO and would not improve, mortality may not always be reflected in microcirculatory changes caused by the underlying disease. In 24 adults with cardiogenic shock treated with VA ECMO, Kara et al. showed that PVD differed between survivors and non-survivors at all-time points ([@B8]). Moreover, in this small group of patients, PVD after start ECMO treatment could predict survival. In a similar population of 48 adults, Yeh et al. found differences in PVD and PPV between survivors and non-survivors ([@B31]). The aforementioned studies only included patients with cardiogenic shock, while our study had a heterogeneous population with fewer cases of cardiogenic shock. The MicroSOAP study, an international study with a heterogeneous adult ICU study population with over 500 patients showed that an abnormal MFI was independently associated with increased mortality risk if patients presented with tachycardia ([@B3]). Similar observations could not be made in our study. Our study may not have had sufficient power to test additional parameters for their predictive value. However, to date there have been no studies on the predictive value of microcirculatory parameters in children, it is therefore uncertain if the microcirculation acts differently in children than in adults. This could be especially true in neonates, as they undergo developmental changes that have not yet been fully investigated ([@B21]--[@B23]). Furthermore, in our study, death was not always a result of cardiorespiratory insufficiency but could also have resulted from irreversible cerebral damage \[*n* = 7 (47%)\] or lack of further therapeutic options \[*n* = 3 (20%)\], such as with refractory pulmonary hypertension or severe heart failure without the option for heart transplantation. These deceased patients did not necessarily have a disturbed microcirculation, which is supported by the finding that the medians and interquartile ranges of microcirculatory parameters of our study population were higher than those of the previously mentioned adult study populations ([@B8], [@B31]). It was therefore unlikely that microcirculatory alterations could predict outcome in this study population.

Whether microcirculatory parameters could also be used in children as a biomarker for successful weaning from ECMO treatment remains unclear. Microcirculatory parameters measured before or after starting ECMO treatment, or on day 2 or 3 could not predict whether a patient could eventually be successfully weaned from ECMO treatment. We were not able to use microcirculatory parameters as a dynamic parameter to assess whether patients could be successfully weaned, as Akin et al. did in adults ([@B9]). Measurements could often not be performed during the desired moment to attempt weaning, as patients were awake. Also, while some institutions routinely perform trial offs to assess whether patients can be weaned from ECMO, our institution gradually decreases ECMO flow rate over time to eventually clamp the ECMO circuit and wean patient from ECMO support.

Our study has some limitations that deserve mention. Although handheld vital microscopy is non-invasive and relatively easy to apply, practical issues account for the missing values at different time points. The feasibility of repeated microcirculatory measurements was limited, as our study population comprised mostly of young patients. It is challenging for young children, while being awake, to remain motionless with their mouth and tongue for several seconds during measurements, causing both movement and pressure artifacts in the recorded imaging. This is especially the case for neonates, as they exhibit a sucking reflex. Often times patients were comfortably sedated but awake, did not cooperate or were too unstable clinically to perform measurements with adequate image quality. This led to the exclusion of 36% of the eligible patients and to missing data in the study population. These challenges are not unique to our study. Gonzalez et al. showed that in a general pediatric ICU population, microcirculatory assessment was only possible in 17% of the patients ([@B32]). These were mostly sedated and stable critically ill children. Additionally, our study population comprised a heterogeneous group of patients in terms of age, diagnosis, type, number, and severity of organ failures and type of ECMO. However, the study population was a representative sample of patients treated in our ECMO program and in many ECMO units around the world (with the exception of units that only use ECMO treatment in designated cardiac patients). Yet, it is possible our study did not have enough power to assess any change over time. Our sample size restricted our multivariable analyses, as we could not correct for all factors involved in these highly complex and critically ill patients. Nevertheless, we were able to explore which covariates possibly influenced the sublingual microcirculation. Future research is necessary to confirm these findings. Another limitation is that our observational study lacked a control group. However, it would have been unethical to randomly allocate severely ill patients to treatment with or without ECMO. Also, assessing whether the microcirculation was disturbed or not was difficult, since reference values for sublingual microcirculatory parameters are lacking. Finally, it should be noted that the sublingual microcirculation might not be reflective of microcirculatory beds of vital organs and this could be one of the explanations why sublingual microcirculatory parameters could not predict outcome. Yet the sublingual microcirculation was and remains an area of interest because of its easy accessibility for non-invasive measurements and alterations in this microcirculatory bed have been shown to be associated with increased morbidity and mortality rates in several different settings including ECMO patients ([@B2], [@B33], [@B34]).

To the best of our knowledge, this study is the first to look at the sublingual microcirculation throughout neonatal and pediatric ECMO treatment. Our study shows that the microcirculation is not solely dependent on global systemic hemodynamics and we have not yet elucidated this highly integrated network of vessels and its role in oxygen transport and tissue oxygenation. This study offers some insight in the applicability and feasibility of handheld vital microscopy in the neonatal and pediatric ECMO population. Our results suggest that the focus of future research should shift from routine monitoring of the microcirculation toward identifying patient populations that could benefit from microcirculatory monitoring, e.g., patients in cardiogenic shock. Evaluating the microcirculation in patients in cardiogenic shock could offer additional guidance for treatment strategies by showing whether inotropic and vasoactive drug support and/or mechanical support can sustain oxygen transport. More homogenous and larger study populations are needed to properly assess the effect of ECMO treatment on the microcirculation through multicenter studies focusing on certain subpopulations who receive ECMO treatment.

Conclusion {#s5}
==========

In our heterogeneous study population, we were not able to demonstrate an effect of ECMO treatment on the sublingual microcirculation. The microcirculation was unaltered throughout ECMO treatment. Microcirculatory parameters did not differ between VV and VA ECMO or between survivors and non-survivors. Although monitoring of the microcirculation with handheld vital microscopy offers additional information on tissue oxygenation, its practice remains challenging in children. Future research should focus on determining which neonatal and pediatric ECMO patients would benefit from microcirculatory monitoring and how.
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ECMO

:   extracorporeal membrane oxygenation

ECPR

:   extracorporeal cardiopulmonary resuscitation

HI

:   heterogeneity index

IS

:   inotrope score

FiO~2~

:   fraction inspired O~2~

MAP

:   mean arterial pressure

MFI

:   microcirculatory flow index

PaCO~2~

:   partial CO~2~ pressure

PaO~2~

:   partial O~2~ pressure

PELOD-2 score

:   pediatric logistic organ dysfunction 2 score

PPV

:   proportion perfused vessels

PVD

:   perfused vessel density

SMC

:   sublingual microcirculation

TVD

:   total vessel density

VA ECMO

:   venoarterial extracorporeal membrane oxygenation

VIS

:   vasoactive-inotrope score

VV ECMO

:   venovenous extracorporeal membrane oxygenation.
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